This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ruilope, L. M Search for Related Content PubMed PubMed Citation Articles by Ruilope, L. M Social Bookmarking                         What's this?

New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease

Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain, Luis_M_Ruilope @teleline.es

Halting the reduction in glomerular filtration rate (GFR) is the primary aim of any treatment of patients presenting with progressive chronic renal failure, a very common corollary to diabetes. To improve GFR, the high blood pressure (BP) and proteinuria often seen in these patients must both be controlled. These symptoms lead not only to progressive loss of renal function, but also to an increase in cardiovascular risk. Use of angiotensin-converting enzyme (ACE) inhibitors in these patients has been reported to control BP and reduce protein excretion and cardiovascular risk. Complete blockade of angiotensin II (Ang II) action with the highly selective Ang II receptor blocker (ARB) valsartan, both as monotherapy and in combination with ACE inhibitors, is well-tolerated and efficacious in patients with renal failure. Unlike ACE inhibition, ARB treatment leads to no initial reduction in GFR, thus valsartan may be a better agent for the control of BP, with greater renal protection.

Key Words: renal failure • Ang II receptor blockade • valsartan • ACE inhibition • diabetes • glomerular filtration rate • microalbuminuria

References

• Plum J., Bünten B., Nemeth R., Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure. J Am Soc Nephrol 1998;9:2223-34.[Abstract]
• Burnier M., Rutschmann B., Nussberger J. et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-47.[Abstract/Free Full Text]
• van der Meiracker AH, Admiraal PJJ, Janssen JA et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9.[Abstract/Free Full Text]
• Sica DA, Hollenberg NK The renal profile of eprosartan. Pharmacotherapy 1999; 19: 86S-94S.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ruilope LM, Aldigier JC,Ponticelli C., Oddou P., Botteri F., Mann JF Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 2000; 18: 89-95.[Web of Science][Medline] [Order article via Infotrieve]
• Russo D., Pisani A., Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-6.[Web of Science][Medline] [Order article via Infotrieve]
• Hebert LA, Falkenhain ME, Nahman NS, Cosio FGJr, O`Dorisio, TM Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19: 1-6.[Medline] [Order article via Infotrieve]
• Cheung R., Lewanczuk RZ, Rodger NW et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract 1999; 53: 584-92.[Web of Science][Medline] [Order article via Infotrieve]
• Baldoncini R., Desideri G., Bellini C. et al. High plasma renin activity is Tcombined with elevated urinary albumin excretion in essential hypertensive patients. Kidney International 1999; 56: 1499-504.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Marre M. Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases.Am JHypertens 1998; 11: 884-6.[CrossRef]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl, S29-S31 (2000)
DOI: 10.3317/jraas.2000.051


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ruilope, L. M Search for Related Content PubMed PubMed Citation Articles by Ruilope, L. M Social Bookmarking                         What's this?